Robocath launches first-in-human clinical study of second-generation coronary robotics system

Robocath has announced the launch of the world’s first First-In-Human (FIH) clinical study assessing its second-generation robotic system for coronary artery disease.

Developed on the back of extensive clinical and technological experience from Robocath’s first robotic platform—already deployed in numerous centers worldwide—the new system introduces unprecedented capabilities tailored to the growing complexity of coronary interventions. The platform is designed to support demanding procedures while maintaining precision, control, and procedural efficiency.

The study will enroll 20 patients with coronary artery disease, primarily complex cases representative of routine catheterization laboratory activity. It will be conducted at the Centre Cardiologique du Nord under the leadership of Dr. Mohammed Nejjari, principal investigator, and Dr. Franck Digne, co-investigator.

Distinguished members of Robocath’s Medical Advisory Board—including Dr. Michael Haude and Dr. Jean Fajadet—will contribute clinical and scientific expertise throughout the program.

“The launch of this First-In-Human study marks a major milestone for Robocath,” said Philippe Bencteux, President of Robocath. “Our second-generation robot builds on the strong clinical and industrial foundations established with our first platform, now used internationally. This world first underscores our leadership and our commitment to advancing interventional robotic technology.”

The global vascular interventional robotics market continues to expand rapidly, driven by demand for minimally invasive procedures, technological advances in robotics, and the rising prevalence of cardiovascular disease. Against this backdrop, the FIH study reinforces Robocath’s ambition to strengthen its global leadership while contributing to the evolution of standards of care for patients with coronary artery disease.

www.robocath.com